Type 1 and 2 Myocardial Infarction and Myocardial Injury: Clinical Transition to High- Sensitivity Cardiac Troponin I Yader Sandoval, MD, Stephen W. Smith,

Slides:

Advertisements

Similar presentations

Low-Dose Aspirin in Patients with Stable Cardiovascular Disease: A Meta-analysis Jeffrey S. Berger, MD, MS, David L. Brown, MD, Richard C. Becker, MD The.

Advertisements

The Epidemic of the 20th Century: Coronary Heart Disease

Mortality Rate in Type 2 Myocardial Infarction: Observations from an Unselected Hospital Cohort Lotte Saaby, MD, Tina Svenstrup Poulsen, MD, PhD, Axel.

Effects of structured care by a pharmacist-diabetes specialist team in patients with Type 2 diabetic nephropathy Wilson Y.S. Leung, BPharm, PhD, Wing-Yee.

Survival probability (%)

Heather C. Brod, MA, Stanley Lemeshow, PhD, Philip F. Binkley, MD, MPH

Long-term Trends in Short-term Outcomes in Acute Myocardial Infarction

Impact of More Restrictive Blood Transfusion Strategies on Clinical Outcomes: A Meta- analysis and Systematic Review Shelley R. Salpeter, MD, Jacob S.

Comparative Effectiveness Research and Medical Informatics

Aruna D. Pradhan, MD, Nader Rifai, PhD, Julie E. Buring, ScD, Paul M

Recurrent infarction causes the most deaths following myocardial infarction with left ventricular dysfunction Stein Ørn, MD, John G.F. Cleland, MD, Matti.

Predicting Survival in Oldest Old People

Significance of Elevated Cardiac Troponin T Levels in Critically Ill Patients with Acute Respiratory Disease Vlad C. Vasile, MD, PhD, High-Seng Chai,

Prevalence, Predictors, and Outcomes in Treatment-resistant Hypertension in Patients with Coronary Disease Sripal Bangalore, MD, MHA, Rana Fayyad, PhD,

The impact of placing multiple grafts to each myocardial territory on long-term survival after coronary artery bypass grafting Danny Chu, MD, Faisal.

Matthew A. Cavender, MD, MPH, Benjamin M

Introduction The American Journal of Medicine

Matthew I. Worthley, MBBS, PhD, FRACP, Fiona M

Elena Biagini, MD, Arend F. L

Systematic Review and Meta-analysis of Adverse Events of Low-dose Aspirin and Clopidogrel in Randomized Controlled Trials Kenneth R. McQuaid, MD, Loren.

Skin Lesion with Splenic Microabscesses in a Patient with Acute Myeloid Leukemia Atul Kothari, MD, Sara C. Shalin, MD, PhD, Juan Carlos Rico Crescencio,

Prognostic Value of Low Blood Glucose at the Presentation of E

CHA2DS2-VASc Score Is Directly Associated with the Risk of Pulmonary Embolism in Patients with Atrial Fibrillation Walid Saliba, MD, MPH, Gad Rennert,

Wandering Acute Myocardial Infarction

Todd A. Lee, PharmD, PhD, Brian Bartle, MPH, Kevin B. Weiss, MD, MPH

Prognostic Importance of Low Admission Serum Creatinine Concentration for Mortality in Hospitalized Patients Charat Thongprayoon, MD, Wisit Cheungpasitporn,

Body Mass Index and Mortality in Acute Myocardial Infarction Patients

Epidemiology of Myelodysplastic Syndromes

A Randomized, Double-Blind, Placebo-Controlled Trial of Nutritional Supplementation During Acute Illness Salah Gariballa, MD, Sarah Forster, MSc, Stephen.

The Impact of Race on the Prognosis of Preclinical Diastolic Dysfunction: A Large Multiracial Urban Population Study Jian Shan, MD, Lili Zhang, MD, MSc,

Laura Sarkisian, MD, Lotte Saaby, MD, PhD, Tina S

The Effect of a Statewide Smoking Ordinance on Acute Myocardial Infarction Rates Paul Basel, BS, Becki Bucher Bartelson, PhD, Marie Claire Le Lait, MS,

The Epidemic of the 20th Century: Coronary Heart Disease

One-hour Rule-in and Rule-out of Acute Myocardial Infarction Using High-sensitivity Cardiac Troponin I Maria Rubini Gimenez, MD, Raphael Twerenbold,

Carotid Sinus Massage in Patients with Suspected Acute Myocardial Infarction, Tachycardia, and Left Bundle Branch Block Teddy Weiss, MD, Yair Elitzur,

Peter K. Wung, MD, Janet T. Holbrook, PhD, MPH, Gary S

Robert Goulden, MBBS, MSc, MPhil, MA The American Journal of Medicine

Peter M. Farrehi, MD, Kristen R. Clore, OTRL, J

Differences in the Clinical Features and Outcomes in African Americans and Whites with Myocardial Infarction Rajendra H. Mehta, MD, MS, David Marks,

Quality of Care for Myocardial Infarction at Academic and Nonacademic Hospitals Loic Belle, MD, José Labarère, MD, Magali Fourny, MSc, Elodie Drouet,

The Reply The American Journal of Medicine

Outcomes of Hospitalized Patients with Non-Acute Coronary Syndrome and Elevated Cardiac Troponin Level Edward O. McFalls, MD, PhD, Greg Larsen, MD, Gary.

Clinical Implication of T2

Carlos Aguilar, MD, Valentin del Villar, MD

Repeated Hemoglobin A1C Ordering in the VA Health System

Resistant Hypertension and the Pivotal Role for Mineralocorticoid Receptor Antagonists: A Clinical Update 2016 Murray Epstein, MD, Daniel A. Duprez,

Early and long-term outcomes of coronary artery bypass grafting in patients with acute coronary syndrome versus stable angina pectoris Toshihiro Fukui,

The Reply The American Journal of Medicine

Yader Sandoval, MD, Stephen W. Smith, MD, Sara A

Trends in Incidence of Hospitalized Acute Myocardial Infarction in the Cardiovascular Research Network (CVRN) Kristi Reynolds, PhD, Alan S. Go, MD, Thomas.

Jennifer Tjia, MD, MSCE, Jeroan Allison, MD, Jane S

Predictors of Intraoperative Hypotension and Bradycardia

Mortality Rate in Type 2 Myocardial Infarction: Observations from an Unselected Hospital Cohort Lotte Saaby, MD, Tina Svenstrup Poulsen, MD, PhD, Axel.

Shannon M. Dunlay, MD, MS, Quinn R. Pack, MD, Randal J

John-Michael Gamble, BScPharm, MSc, Dean T. Eurich, PhD, Thomas J

Evaluation of Severe Infection and Survival After Splenectomy

Heather C. Brod, MA, Stanley Lemeshow, PhD, Philip F. Binkley, MD, MPH

Plasma Lactescence in Acute Pancreatitis

Acute Reperfusion Therapy in ST-Elevation Myocardial Infarction from

Primary Care Management of Skin Abscesses Guided by Ultrasound

Risk Estimation in Type 2 Myocardial Infarction and Myocardial Injury: The TARRACO Risk Score German Cediel, MD, PhD, Yader Sandoval, MD, Anne Sexter,

Determining Triglyceride Reductions Needed for Clinical Impact in Severe Hypertriglyceridemia Jennifer B. Christian, PharmD, MPH, PhD, Bhakti Arondekar,

Falls in Older Adults: Risk Assessment, Management and Prevention

Matthew W. Martinez, MD, Keith G. Rasmussen, MD, Paul S

Prevalence and Significance of Unrecognized Renal Dysfunction in Patients with Acute Coronary Syndrome Zach Rozenbaum, MD, Avi Leader, MD, Yoram Neuman,

Bijin Thajudeen, MD, Mario F. Rubin, MD

Preoperative Thienopyridine Use and Outcomes after Surgery: A Systematic Review Anita G. Au, MD, Sumit R. Majumdar, MD MPH, Finlay A. McAlister, MD MSc

Significance of Comorbid Psychological Stress and Depression on Outcomes After Cardiac Rehabilitation Sergey Kachur, MD, Arthur R. Menezes, MD, Alban.

Effects of structured care by a pharmacist-diabetes specialist team in patients with Type 2 diabetic nephropathy Wilson Y.S. Leung, BPharm, PhD, Wing-Yee.

Secular trends in cardiovascular disease mortality, incidence, and case fatality rates in adults in the United States Ahmet Ergin, MD, PhD, MPH, Paul.

Presentation transcript:

Type 1 and 2 Myocardial Infarction and Myocardial Injury: Clinical Transition to High- Sensitivity Cardiac Troponin I Yader Sandoval, MD, Stephen W. Smith, MD, Anne Sexter, MPH, Sarah E. Thordsen, MD, Charles A. Bruen, MD, Michelle D. Carlson, MD, Kenneth W. Dodd, MD, Brian E. Driver, MD, Yan Hu, PhD, Katherine Jacoby, MD, Benjamin K. Johnson, MD, Sara A. Love, PhD, Johanna C. Moore, MD, Karen Schulz, DC, Nathaniel L. Scott, MD, Fred S. Apple, PhD The American Journal of Medicine Volume 130, Issue 12, Pages 1431-1439.e4 (December 2017) DOI: 10.1016/j.amjmed.2017.05.049 Copyright © 2017 Elsevier Inc. Terms and Conditions

Figure 1 One hundred eighty-day all-cause mortality and postdischarge major adverse cardiac events comparing patients without myonecrosis with type 1 myocardial infarction, type 2 myocardial infarction, and myocardial injury. MACE = major adverse cardiovascular event. The American Journal of Medicine 2017 130, 1431-1439.e4DOI: (10.1016/j.amjmed.2017.05.049) Copyright © 2017 Elsevier Inc. Terms and Conditions

Figure 2 One hundred eighty-day Kaplan-Meier survival curve for patients without myonecrosis (no myocardial infarction with cTnI <99th percentile), type 1 myocardial infarction, type 2 myocardial infarction, and myocardial injury. cTnI = cardiac troponin I. The American Journal of Medicine 2017 130, 1431-1439.e4DOI: (10.1016/j.amjmed.2017.05.049) Copyright © 2017 Elsevier Inc. Terms and Conditions

Figure 3 Two-year Kaplan-Meier survival curve for type 1 myocardial infarction, type 2 myocardial infarction, and myocardial injury. The American Journal of Medicine 2017 130, 1431-1439.e4DOI: (10.1016/j.amjmed.2017.05.049) Copyright © 2017 Elsevier Inc. Terms and Conditions

Figure 4 Predictors of long-term mortality for type 2 myocardial infarction. ACE = angiotensin-converting enzyme. The American Journal of Medicine 2017 130, 1431-1439.e4DOI: (10.1016/j.amjmed.2017.05.049) Copyright © 2017 Elsevier Inc. Terms and Conditions

Figure 5 Predictors of long-term mortality for myocardial injury. ACE = angiotensin-converting enzyme. The American Journal of Medicine 2017 130, 1431-1439.e4DOI: (10.1016/j.amjmed.2017.05.049) Copyright © 2017 Elsevier Inc. Terms and Conditions

Figure 6 Incidence of myocardial necrosis (≥1 cTnI >99th percentile), acute myocardial infarction, type 1 myocardial infarction, type 2 myocardial infarction, and myocardial injury using a contemporary vs hs-cTnI assay. cTnI = cardiac troponin I. The American Journal of Medicine 2017 130, 1431-1439.e4DOI: (10.1016/j.amjmed.2017.05.049) Copyright © 2017 Elsevier Inc. Terms and Conditions